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Guidance from the Institute for Quality and Efficiency in Health Care (IQWiG) on cost estimation in cost–benefit assessments
in Germany acknowledges the need for standardization of costing methodology. The objective of this review was
to assess current methods for deriving clinical event costs in German economic evaluations. A systematic literature
search of 24 databases (including MEDLINE, BIOSIS, the Cochrane Library and Embase) identified articles, published
between January 2005 and October 2009, which reported cost-effectiveness or cost-utility analyses. Studies assessed
German patients and evaluated at least one of 11 predefined clinical events relevant to patients with diabetes
mellitus. A total of 21 articles, describing 199 clinical cost events, met the inclusion criteria. Year of costing and time
horizon were available for 194 (97%) and 163 (82%) cost events, respectively. Cost components were rarely specified
(32 [16%]). Costs were generally based on a single literature source (140 [70%]); where multiple sources were cited
(32 [16%]), data synthesis methodology was not reported. Cost ranges for common events, assessed using a Markov
model with a cycle length of 12 months, were: acute myocardial infarction (nine studies), first year, 4,618–17,556 €;
follow-up years, 1,006–3,647 €; and stroke (10 studies), first year; 10,149–24,936 €; follow-up years, 676–7,337 €.
These results demonstrate that costs for individual clinical events vary substantially in German health economic
evaluations, and that there is a lack of transparency and consistency in the methods used to derive them. The
validity and comparability of economic evaluations would be improved by guidance on standardizing costing
methodology for individual clinical events.
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In Germany, the Institute for Quality and Efficiency in
Health Care (IQWiG) has been legally empowered to as-
sess the increase in benefit as well as the relationship of
benefits and costs for drugs and healthcare procedures.
IQWiG has recently published a working paper on cost
estimation in cost–benefit assessments in Germany [1].
In this document, it is acknowledged that there is poten-
tial for standardization of costing methodology to im-
prove the comparability of health economic evaluations.
Lists of agreed unit costs (so-called standard cost lists)
that supplement guidelines for health economic break at
evaluation in other countries (e.g. Australia [2], Canada
[3,4], and the Netherlands [5]) are cited as examples of
such standardization. In addition, the ‘Methods in Health* Correspondence: monika.scheuringer@msd.de
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have developed an approach to standardizing cost esti-
mates [6]. In general, however, such lists do not com-
prise agreed costs for frequently observed clinical events
as estimates for the actual costs accrued (so-called costs
for clinical events).
Costs for clinical events are essential for creating
health economic models that are able to accurately
simulate both the health outcomes and cost of different
treatment options by incorporating evidence from a var-
iety of sources. Ideally, the way in which these costs are
obtained and the cost components included, should be
described in the reporting of each study. We conducted
a systematic literature review of costs for clinical events
used in health economic evaluations in Germany from
2005 to 2009 in order to provide insight into thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Scheuringer et al. Cost Effectiveness and Resource Allocation 2012, 10:7 Page 2 of 13
http://www.resource-allocation.com/content/10/1/7derivation of these costs and to assess the potential for
providing future standard lists for clinical events.
Methods
Identification of relevant studies
A systematic literature review was conducted to deter-
mine the costs for clinical events that are relevant to
patients with diabetes mellitus, according to Preferred
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) literature review methodology [7].
Diabetes mellitus has a significant economic burden and
it was assumed that an adequate number of health eco-
nomic analyses in this disease area would have been
published in the time frame of interest to enable an ana-
lysis of costs to be performed. Typically such health eco-
nomic models include a range of disease stages and
provide invaluable insight into the derivation of costs of
clinical events. In total, 24 databases, including MED-
LINE, BIOSIS, the Cochrane Library and Embase (see
Additional file 1), were searched for articles published
between January 2005 and October 2009. The reference
lists of systematic reviews and meta-analyses identified
were screened independently by two researchers to as-
sess whether they included health economic evaluations
that met the criteria for inclusion; disagreements were
resolved after discussion between the two researchers.
The final search was conducted on 30 October 2009.
Articles were included in this review if they: were eco-
nomic analyses reporting an incremental cost-
effectiveness ratio (ICER); included German patients
aged at least 18 years; were published in 2005 or later in
English or German; and evaluated at least one of 11 pre-
defined clinical events (acute myocardial infarction [MI],
stroke, angina pectoris, heart failure, microalbuminuria
and/or macroalbuminuria, renal failure, cataract, retin-
opathy, blindness, neuropathy, and amputation owing to
diabetic foot syndrome). Only full text published articles
were included in the review; abstracts referencing con-
gress presentations were excluded. The flow of studies
through the systematic review is shown in Figure 1.
Information extraction and analysis
In order to examine the ability of the extracted costs to
inform future standard lists for clinical events, the char-
acteristics of the health economic evaluations (type of
economic evaluation, model type, time horizon, cycle
length, target population, severity of health status, type
of intervention, outcome measure, perspective of ana-
lysis, primary time horizon, secondary time horizon, type
of sensitivity analysis), costs for clinical events, and der-
ivation of these costs (time horizon covered, cost com-
pounds covered, year of cost data, currency conversion
rate, inflation rate) were extracted using a Microsoft Ac-
cess database structured form. The maximum andminimum costs used in Markov models that had a cycle
length of 12 months were then summarized in a table,
with stratification by first cycle and follow-up cycles.
Results
Identification of relevant studies
In total, 616 articles were identified from database
searches, and one further article was identified through
hand-searching of reference lists from systematic reviews
and meta-analyses. Of the 617 articles identified, 485
were excluded based on the title or abstract, and a fur-
ther 111 articles were excluded after evaluation of the
full text; 21 articles were therefore included in the final
review (Figure 1).
Study characteristics
The study characteristics of the included articles are
described in Table 1. Ten articles reported cost-utility
analyses, nine reported cost-effectiveness analyses, and
two reported findings from both types of economic ana-
lysis. Overall, 19 analyses were undertaken from the
payer perspective, one from the societal perspective, and
in one article the perspective was not specified. Most
articles reported the results of Markov (n= 12) or semi-
Markov models (n= 5). Four articles reported results
from a decision tree, two of which also included Markov
modelling.
Information extraction and analysis
In total, 199 costs for clinical events were identified.
Details on costs for acute MI and stroke are shown in
Table 2 and Table 3, respectively; details on costs for all
other clinical events are provided in Additional file 2.
The year of costing and the time horizon covered were
available for 194 (97%) and 163 (82%) costs, respectively.
The cost components covered (e.g., hospitalization, re-
habilitation) were specified for only 32 costs (16%); the
inflation rate applied was not reported in any of the
studies. In most cases (n= 140 [70%]), the costs were
based on a single literature source. Multiple sources
were cited for 32 costs; however, information on data
synthesis was not reported. Sources were not stated for
27 costs (14%). Journal articles were the most common
source for the derivation of costs (n= 153 [77%]), fol-
lowed by healthcare system reports (n= 30 [15%]) and
web pages (n= 24 [12%]). Of the 35 journal articles that
were cited, 19 were cost-of-illness studies (54%).
Costs for clinical events
There was considerable variation among the publications
in the costs allocated to the clinical events of interest.
This variation remained even when findings were filtered
to group similar studies together. Table 4 shows the dif-
ferences in the minimum and maximum costs cited for
Figure 1 Flow chart of included studies.
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that had a cycle length of 12 months, and which
excluded costs for fatal events, transient ischaemic at-
tack and silent MI. Costs for each clinical event are con-
sidered in more detail below.
Acute MI
In total, 39 costs for acute MI were reported in 16 stud-
ies (Table 2). One study included the cost of a silent MI,
which was considered to be zero (0 €) [25]. The cost of
an acute MI ranged widely. Even if only those studies
that used a Markov model with a cycle length of
12 months were included (n= 9), the costs for the first
cycle still varied considerably, ranging from 4,618 € to
17,556 € (Table 4) [12,14,19,23-28].
Angina pectoris
Five studies reported a total of five costs for angina pec-
toris (Additional file 2) [18,19,23,26,27]. First cycle costs
varied widely, ranging from 3,274 € to 6,840 €. The vari-
ation in costs persisted when only those studies that
used a Markov model with a cycle length of 12 months
were included (Table 4).
Stroke
The largest number of costs was reported for stroke: 19
studies reported a total of 55 costs (Table 3). Large var-
iations were observed in the costs attributed to both the
first and follow-up cycles for a non-fatal stroke (i.e., ex-
cluding fatal events and transient ischaemic attack). Even
when only those studies that used a Markov model with
a cycle length of 12 months were included, costs still
varied considerably, ranging from 10,149 € to 24,936 €,and 676 € to 7,337 €, for the first and follow-up cycles,
respectively (Table 4).
Heart failure
Six studies reported a total of seven costs for heart fail-
ure (Table 4; Additional file 2) [18,19,23,25,27,28]. When
only costs from Markov models were included, and non-
serious heart failure or hospitalization-only costs were
excluded, the costs for the first and follow-up cycles ran-
ged from 2,859 € to 6,291 € and 800 € to 4,372 €, re-
spectively [19,23,27,28]; the cost components for these
studies were not specified.
Microalbuminuria and macroalbuminuria
No studies reported costs for microalbuminuria or
macroalbuminuria.
End-stage renal disease
Overall, 31 costs for end-stage renal disease were reported
across eight studies (Additional file 2) [15,19,22-25,27,28].
Costs were reported for several different levels of dis-
ease severity: renal transplantation, re-transplantation,
dialysis, haemodialysis and peritoneal dialysis. End-stage
renal disease had the highest reported costs of all of the
clinical events evaluated in this review. In most cases,
the cost components covered were not specified. The
variation could not be accounted for by differences in
disease severity, as it persisted when costs were categor-
ized by transplantation (first-cycle costs 45,636–76,135
€) [19,23-25,27] or dialysis (46,296–63,696 €) [19,23-
25,27,28]. However, costs for follow-up cycles were con-
sistently lower in transplantation patients than in dialy-
sis patients (9,129–13,176 € vs. 46,296–61,230 €).
Table 1 Included studies
Study Patients Intervention Health states evaluated Perspective Time horizon





Berg et al. 2007 [9] STEMI Clopidogrel + ASA • MI Societal 1 year
• Stroke
Berg et al. 2008 [10] ACS undergoing PCI Clopidogrel + ASA • MI Payer Not specified
• Stroke





Brüggenjürgen et al. 2007 [12] ACS without ST-elevation Clopidogrel + ASA • MI Payer Lifetime
• Stroke
Claes et al. 2008 [13] Stroke Dipyridamole + ASA • Stroke Payer Lifetime
Gandjour et al. 2007 [14] Hypertension at high or






Jürgensen et al. 2009 [15] Dialysis Immunosuppressive
therapy – sirolimus
• End-stage renal disease Payer 2 years
Lamotte et al. 2006 [16] CVD ASA • MI Payer 10 years
• Stroke
Lamotte et al. 2006 [17] MI n-3 PUFA post-MI • MI Payer 3.5 years
• Stroke




Mittendorf et al. 2009 [19] Type 2 DM Exenatide • Angina pectoris Payer 10 years
• Blindness
• Cataract
• Diabetic foot syndrome






Neeser et al. 2006 [20] Atrial fibrillation Oral vitamin K antagonists • Stroke Not specified 10 years
Rasch et al. 2009 [21] Smoking Varenicline • Stroke Payer Lifetime
Rosery et al. 2006 [22] Secondary hyperparathyroidism
during haemodialysis
Paricalcitol (i.v.) • End-stage renal disease Payer 1 year
Roze et al. 2006 [23] Insulin-naïve type 2 DM Acarbose + diet • Angina pectoris Payer 35 years
• Blindness
• Cataract
• Diabetic foot syndrome
• End-stage renal disease
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Schaufler 2009 [24] Type 2 DM Type 2 DM prevention • Blindness Payer 1 year
• Diabetic foot syndrome









• Diabetic foot syndrome






Schwander et al. 2009 [26] CVD Eprosartan • Angina pectoris Payer Lifetime
• MI
• Stroke






• Diabetic foot syndrome










• Diabetic foot syndrome






ACS= acute coronary syndromes; ASA= acetylsalicylic acid; CVD= cardiovascular disease; DM=diabetes mellitus; IGT= impaired glucose tolerance; i.v. =
intravenous; MI=myocardial infarction; PCI=percutaneous coronary intervention; PUFA=polyunsaturated fatty acids; STEMI = ST-elevation myocardial infarction.
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Year of costing: 2003
















2,880 NA Yes No follow-up costs
considered





















3,123 NA Yes Annual follow-up
costs
1,907 1
Liebl A. Gesund ökon












Year of costing: 2004
Lamotte M.
Pharmacoeconomics




















4,618 > 1 Yes Post-year 1 2,014 > 1
Brüggenjürgen B. Eur
J Health Econ





11,241 1 Yes Yes Yes Annual follow-up
costs
1,006 1







15,011 > 1 Yes Annual follow-up
costs
1,168 1
Year of costing: 2005
Scherbaum WA. Cost
Eff Resour Alloc
2009; 7: 9 [25]
Semi-Markov
model
Silent MI Year of
event
0 NA Yes No follow-up costs
considered






MI Month 1 6,799 > 1 Yes Months 2–12 5,129 1
Berger K. Curr Med
























8,635 1 Yes Annual follow-up
costs
3,647 1
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16,767 1 Yes Year after event 1,253 1


















17,556 1 Yes Annual follow-up
costs
2,323 1




























11,683 > 1 Yes Annual follow-up
costs
2,803 > 1
a Number of data sources from which unit costs were retrieved.
b No indirect unit costs could be retrieved.
hosp=hospital; MI=myocardial infarction; NA=not available; rehab= rehabilitation.
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Eleven costs for blindness were reported across six stud-
ies (Additional file 2) [19,23-25,27,28]. Costs ranged
from 8,685 € to 11,745 € for the first cycle, and from
5,092 € to 11,017 € for subsequent follow-up cycles. The
variation in costs persisted when only those studies that
used a Markov model with a cycle length of 12 months
were included (Table 4).
Retinopathy
Only three studies gave costs for retinopathy (Additional
file 2) [24,25,28]. Costs for the first cycle were 1,862–
3,904 €. Only one study reported costs for follow-up
cycles (340 € for hospitalization) (Table 4) [25].
Cataract
Costs for cataract varied considerably (Table 4; Add-
itional file 2) [19,23,25,27,28]. However, most studies did
not specify the time horizon, thereby limiting the useful-
ness of cross-study comparisons. In addition, the cost
components covered were not usually specified. Gener-
ally, studies cited only a single reference for unit cost.
Two studies gave costs for hospitalization (755–1,686 €),
but neither cited a source [19,28].
Neuropathy
Five studies reported costs for neuropathy [19,23,25,27,28]
(Additional file 2). With one exception (first cycle 304 €),the costs were fairly consistent (first cycle of other four
studies, 3,855–4,091 €), however, the cost components
covered were not specified.Diabetic foot syndrome
In total, 21 costs were reported for diabetic foot syn-
drome, across six studies (Additional file 2) [19,23-
25,27,28]. Costs were specified for various disease sever-
ities, including gangrene, infected ulcer, uninfected ulcer,
healed ulcer and amputation. Costs were almost all
based on single references, and generally increased with
disease severity (first-cycle costs: healed ulcer, 46–47 €
[23,27]; uninfected ulcer, 877–1,210 € [19,23,25,27];
infected ulcer, 1,784–5,217 € [19,23,25,27]; and gan-
grene, 3,186–13,056 €) [19,23,25,27]. In studies that used
a Markov model with a cycle length of 12 months, the
cost for the first cycle for amputation ranged from
15,405 € to 24,818 € (Table 4). The reasons for the vari-
ability in costs are unclear, as the cost components cov-
ered were not specified.Discussion
This first systematic review of costs for clinical events
used in health economic evaluations in Germany shows
substantial cost variability. Exact reasons for these differ-
ences are unclear, because of the generally insufficient
level of methodological information regarding source
data for costing of events in published health economic
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1,897 NA Yes No follow-up
costs considered





















3,390 NA Yes Annual follow-up
costs
676 1
Liebl A. Gesund ökon










Year of costing: 2004
Lamotte M.
Pharmacoeconomics.





3,390 1 Yes No follow-up
costs considered









9,006 1 Yes No follow-up
costs considered






10,149 > 1 Yes Annual follow-up
costs
4,364 > 1







17,734 1 Yes Yes Yes Annual follow-up
costs
5,614 1

















24,936 > 1 Yes Post-year 1 5,465 > 1
Year of costing: 2005
Scherbaum WA. Cost Eff






2,354 NA Yes Annual follow-up
costs
0 NA








2,500 NA Yes No follow-up
costs considered






7,000 NA Yes Rehab after acute
event
7000 NA
Scherbaum WA. Cost Eff






10,524 > 1 Yes Annual follow-up
costs
6,178 > 1
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Table 3 Costs for stroke, 2003–2007, Germany (Continued)







20,811 1 Yes Year after event 6,501 1



































Year of costing: 2006
Valentine WJ. Adv Ther
















18,649 1 Yes Annual follow-up
costs
4,416 1
Valentine WJ. Adv Ther





20,439 1 Yes Annual follow-up
events
6,385 1































































Year of costing: not specified
Neeser K. J Kardiol























4,679 1 Yes From second
year onwards
12,500 1
a Number of data sources from which unit costs were retrieved.
b No indirect unit costs could be retrieved.
hosp=hospital; rehab= rehabilitation; NA=not available; TIA= transient ischaemic attack.
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Table 4 Costs for clinical events used in Markov models with a cycle length of 12 months
Health state First cycle Follow-up cycles
na Minimum (€) Maximum (€) na Minimum (€) Maximum (€)
Acute myocardial infarction 9 4,618 17,556 9 1,006 3,647
Angina pectoris 4 3,342 6,840 4 1,315 6,840
Stroke 10 10,149 24,936 10 676 7,337
Heart failure 4 2,859 6,291 3 800 2,859
Microalbuminuria/macroalbuminuria 0 — — 0 — —
End-stage renal disease: renal transplantation 5 45,636 76,135 5 9,129 11,448
Blindness 4 8,685 11,745 2 5,331 10,661
Retinopathy 3 1,862 3,904 1 340 340
Cataract 2 755 1,348 1 0 0
Neuropathy 5 304 4,091 0 — —
Diabetic foot syndrome: amputation 4 15,405 24,818 2 3,304 3,639
a Number of event costs identified.
Costs for fatal events, silent myocardial infarction and transient ischaemic attack have been excluded.
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German health economic analyses are therefore insuffi-
cient for establishing future standard lists for such
events.
Our findings are consistent with the conclusions of
Ray et al. that there is considerable internal heterogen-
eity in both costs and clinical values in countries lacking
an established nationwide system of reporting health
outcomes [29]. Our observation that the derivation of
costs is generally not explicitly defined in German ana-
lyses was also consistent with a review of published eco-
nomic evaluations available in the European Network of
Health Economics Evaluation Database [30]. Ideally,
event costs should be derived from a robust cost-of-
illness study conducted in the same patient population
country and setting, and with the same disease severity
and treatment algorithm, as the economic evaluation.
Typically, however, published cost-of-illness studies do
not meet these criteria, and the derived event costs are
adjusted for local differences (for example, in treatment
pattern, definition of clinical event and disease severity).
While this is an acceptable approach, it is essential that
the methodology for adjusting the original event costs is
clearly defined and supported, and that cost corrections
for inflation and currency conversion are performed.
Our review shows that most event costs are not based
on comprehensive cost-of-illness studies, but on previ-
ous cost-effectiveness or cost-utility analyses. While this
is by far the simplest approach to obtaining event costs,
it raises issues as to whether the previously published
cost is appropriate for the new analysis, and was itself
derived appropriately.
Accurate and consistent assessment of costs is essen-
tial in countries such as Germany that are movingtowards early benefit evaluations and cost–benefit ana-
lyses of new products relative to current standards of
care; hence, there is a clear need to consider how the
methodology for estimating costs of clinical events could
be improved to ensure that health economic evaluations
provide robust, realistic and comparable outputs. What
methods can be applied to achieve consensus on costs
for clinical events? It is clear that guidance on the deriv-
ation of costs should be fully transparent, updated regu-
larly and in the public domain. Three alternatives can be
considered.
Standard cost lists for most relevant medical/non-medical
goods or services only
Standard lists of agreed unit costs for medical/non-med-
ical goods or services are provided by multiple countries,
including Australia and the Netherlands, and are accom-
panied by guidance documents on the fundamental
process for costing of events [2,5]. This flexible approach
enables the evaluation of event costs according to different
perspectives and patient subgroups. In countries where
healthcare systems are decentralized, cost lists may need
to be developed within each major region rather than at a
national level; a study in Canada showed the difficulties in
consolidating cost lists across two provinces [3].
Standard cost models for relevant clinical events, in
addition to standard cost lists for the most relevant
medical/non-medical goods or services
A similar approach is taken by the UK National Health
Service (NHS), which publishes detailed annual reports
of reference costs [31]. The UK National Institute
for Health and Clinical Excellence (NICE) mandates
that economic evaluations performed for UK Health
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agement of the condition is currently costed in the NHS
in terms of these reference costs, and with regard to the
relevant Healthcare Resource Group (HRG). This frame-
work for developing costs of clinical events utilizing
reference data provides some degree of standardization;
however, it is binding only for submissions to NICE, and
does not necessarily apply to independent economic eva-
luations that may ultimately influence decision-making.
Moreover, it does not cover resource utilization or costs
where the HRG is inappropriate (e.g., too broad or not
reflective of resource use related to the treatment in
question); in these cases, the NICE guidance document
suggests using other sources of evidence, such as micro-
costing studies. Such cost data may be taken from
current literature, provided that the methods used to
identify sources are clearly defined, and that sensitivity
analysis are used to assess the implications of using al-
ternative data sources [32]. A recent systematic review
of primary research studies funded by the UK HTA
programme showed that the majority of studies (72 out
of 95 evaluated) obtained source costs from the annual
compendium of Unit Costs of Health and Social Care
[33]; 52 studies used costs that had been sourced locally
(mainly NHS trusts) and 36 of the 95 studies used data
from HRGs [34].
Standard cost lists for relevant clinical events, in addition
to standard cost lists for the most relevant medical/non-
medical goods or services
A recent feasibility study confirmed the potential for
developing standardized diagnosis-specific cost lists for
clinical events based on publicly available actual expen-
ditures in the German healthcare system [35]. Costs
were derived from the Information System of the Federal
Health Monitoring, utilizing the fact that official 2006
cost-of-illness accounts (www.gbe-bund.de) provide
healthcare expenditures categorized according to the Or-
ganisation for Economic Co-operation and Development
health accounts (ambulatory care, stationary/semi-sta-
tionary healthcare, ambulance services, administration,
other providers and private households), as well as
according to the three-digit codes of the International
Statistical Classification of Diseases and Related Health
Problems 10th revision. Although increased data avail-
ability from Federal Health Monitoring will likely lead to
expansion of these standard lists, this approach may
prove too inflexible to take into account the divergent
nature of patient populations and perspectives consid-
ered in health economic evaluations.
The strengths and limitations of the present study
must be considered. Key strengths are that this was a
systematic review of all available evidence, considering a
clearly defined set of clinical events (related to diabetesmellitus) and studies (cost-utility and cost-effectiveness
analyses) conducted from a German perspective. The
analysis had a limited focus, in that it included only fully
published economic analyses reporting an ICER (i.e.,
cost-of-illness studies were excluded); however, this was
intentional in order to reflect the decision-maker per-
spective. A number of studies were excluded from the
analysis on the basis that the results had only been pub-
lished in abstract form, rather than as a full text article,
indicating that there is limited access to details of
country-level health economic evaluations. Other limita-
tions include the fact that our analysis considered only
11 events within a single disease area. Although it seems
reasonable to expect that the observed variability in
event costs may be generalized to other disease areas,
this cannot be concluded with certainty from the current
study. Moreover, it was often difficult to judge whether
comparisons were fair because of the lack of clarity over
exactly how individual studies assessed costs and the na-
ture of their data sources.
Conclusions
This first systematic review of costs used in health eco-
nomic evaluations in Germany shows substantial vari-
ability in costs for individual clinical events, and a lack
of transparency and consistency in the methods used to
derive those costs. Ideally, the derivation of costs for
clinical events should be fully transparent, based on ac-
tual expenditure, updated regularly and in the public do-
main. While a full standard cost list for clinical events
would not be constructive because it is unclear how
costs for events vary according to patient group, per-
spective, and other relevant factors such as knowledge
and experience in the therapeutic field of interest, the
validity and cross-comparability of health economic eva-
luations would be considerably improved by national- or
regional-level guidance on standardization of the costing
methodology of individual clinical events.
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